Trial intelligence / Profile preview

DPI-386 Nasal Gel for Motion Sickness

NCT04184115Phase 3Completed

Sponsor
Defender Pharmaceuticals
Start
Jun 2019
Primary completion
Jun 2019
Modality
Placebo
Countries
1
01

Overview

A Phase 3 trial of placebo gel (Naval Aeromedical Research Unit, Dayton) in motion sickness, sponsored by Defender Pharmaceuticals. Started Jun 2019; status: completed.

02

Drugs

placebo gel (Naval Aeromedical Research Unit, Dayton)
03

Conditions

motion sickness

Beyond the preview

Go deeper on NCT04184115.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT04184115.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call